Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

All Conditions

Rare Diseases

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Endocrine System Diseases

Gonadal Disorders

Ovarian Cancer

Ovarian Epithelial Cancer

Antineoplastic Agents

All Drugs and Chemicals

Anti-Infective Agents

Gemcitabine

Paclitaxel

Albumin-Bound Paclitaxel

Doxorubicin

Liposomal doxorubicin

Topotecan

Tubulin Modulators

Antimitotic Agents

Antimetabolites

Anti-Bacterial Agents

Antibiotics, Antitubercular

Enzyme Inhibitors

Topoisomerase I Inhibitors

Patients receive BI 6727 infusion every 3 weeks

At the investigator discretion, patient will receive one of the following cytotoxics: topotecan, paclitaxel, gemcitabine or liposomal doxorubicin

Patients receive paclitaxel in a 4 week schedule

Patients receive gemcitabine in a 3 week schedule

Patients receive topotecan in 3 or 4 week schedule

Patients receive PLD in a 4 week schedule

Pegylated liposomal doxorubicin (PLD)

BI 6727

Boehringer Ingelheim

This is an international, randomized phase II trial. The aim is to assess the efficacy and the safety of BI 6727 Versus investigator's best choice single agent cytotoxic in recurrent third and fourth lines platinum resistant/refractory ovarian cancer.

100 patients will be randomised at the study entry to receive either BI 6727 (Arm A: 50 patients) or non-platinum single agent cytotoxic (Arm B: 50 patients) Treatment will be continued until disease progression or unacceptable toxicity. Primary endpoint: disease control rate at week 24 according to Response Evaluation Criteria In Solid Tumours version 1.1.

Secondary endpoints: efficacy (progression free survival, overall survival, biological tumour response, biological progression free survival assessed by serum CA 125 according to Gynecologic Cancer Intergroup criteria, safety according to the NCI CTCAE v.3, disease symptoms control assessed by the EORTC QLQ-C30, QLQ-OV28 and individual symptoms questionnaires, pharmacokinetics of BI 6727.

Others endpoints: biomarkers and pharmacogenetics analysis (optional)

BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer

Phase II Randomized Trial of the Polo-like Kinase 1 Inhibitor BI 6727 Monotherapy Versus Investigator´s Choice Chemotherapy in Ovarian Cancer Patients Resistant or Refractory to Platinum-based Cytotoxic Therapy

DCR was defined as the proportion of patients who had an overall response of complete response (CR), partial response (PR), or stable disease (SD).

Progression-free survival of a patient was based on the investigator's assessment; it was defined as the number of days from the date of randomisation until the date of either disease progression or death from any cause, whichever occurred first.

Definition of disease progression according to RECIST version 1.1; Patients with measurable tumour lesions at baseline, Target-lesions: at least a 20% increase in the sum of diameters of target lesions, the sum of diameters must also demonstrate an absolute increase of at least 5 mm,taking as reference the smallest sum on study, or appearance of 1 or more new lesions.

Non-target lesions: unequivocal progression of existing non-target lesions or appearance of 1 or more new lesions Patients with non-measurable tumour lesions at baseline, Non-target lesions: requires unequivocal progression of existing non-target lesions or appearance of 1 or more new lesions

OS is defined as time from randomisation to death irrespective of the cause of the death.

Best overall response (BOR) is defined as the best response recorded at any time from the date of randomisation until the end of treatment.

Missing categories signify that no tumour imaging has been performed post baseline, and therefore the response status could not be assessed.

Patients were to have a pre-treatment CA-125 of at least twice the upper limit of normal to be considered for CA-125 response. Patients were not evaluable by CA-125 if they had received mouse antibodies or if they had undergone medical and/or surgical interference with their peritoneum or pleura during the previous 28 days. In eligible patients, a CA-125 response was defined as the moment the CA- 25 was reduced by 50%, with this being confirmed with a consecutive CA-125 assessment not earlier than 28 days after the previous one.

Biological response rate based on serum CA-125 levels was assessed according to the guidelines by the Gynaecologic Cancer Intergroup. Monitoring of blood levels of the tumour marker CA-125 was performed at screening and every 6 weeks thereafter.

Biological PFS including assessment of CA-125 levels was defined as the time from randomisation until the first occurrence of progressive disease according to CA-125, progressive disease according to radiological evidence, or death.

Also according to the below criterias,

* In patients with radiological measurable disease, disease progression during study treatment could not be declared on the basis of CA-125 alone.
* Patients with elevated CA-125 pre-treatment and normalization of CA-125 had to show evidence of CA-125 ≥ to two times the upper normal limit on two occasions at least one week apart or
* Patients with elevated CA-125 pre-treatment, which never normalized, had to show evidence of CA-125 ≥ to two times the nadir value on two occasions at least one week apart or
* Patients with CA-125 in the normal range pre-treatment had to show evidence of CA-125 ≥ to two times the upper normal limit on two occasions at least one week apart.

Time to deterioration in global health status/Quality of life (QOL) and symptom control assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, QLQ-OV28, and individual symptom questionnaires.

The time to deterioration was defined as the time from randomisation to a score increased (i.e. worsened) by at least 10 points from baseline (0-100 point scale). If score is missing, and patient died within 28 days after scheduled time for completion, the patient was considered deteriorated. In this case, time to deterioration is time to death.

Time to deterioration in fatigue/Quality of life (QOL) and symptom control assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, QLQ-OV28, and individual symptom questionnaires.

The time to deterioration was defined as the time from randomisation to a score increased (i.e. worsened) by at least 10 points from baseline (0-100 point scale). If score is missing, and patient died within 28 days after scheduled time for completion, the patient was considered deteriorated. In this case, time to deterioration is time to death.

Time to deterioration in pain/ Quality of life (QOL) and symptom control assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, QLQ-OV28, and individual symptom questionnaires.

The time to deterioration was defined as the time from randomisation to a score increased (i.e. worsened) by at least 10 points from baseline (0-100 point scale). If score is missing, and patient died within 28 days after scheduled time for completion, the patient was considered deteriorated. In this case, time to deterioration is time to death.

Time to deterioration in abdominal bloating/ Quality of life (QOL) and symptom control assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, QLQ-OV28, and individual symptom questionnaires.

The time to deterioration was defined as the time from randomisation to a score increased (i.e. worsened) by at least 10 points from baseline (0-100 point scale). If score is missing, and patient died within 28 days after scheduled time for completion, the patient was considered deteriorated. In this case, time to deterioration is time to death.

Three most troublesome disease specific symptoms, defined by the patient at baseline.

Patients that have defined more than 3 most troublesome symptoms have not been taken into account in the analysis.

Quality of life (QOL) and symptom control assessed by the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, QLQ-OV28, and individual symptom questionnaires.

The time to deterioration was defined as the time from randomisation to a score increased (i.e. worsened) by at least 10 points from baseline (0-100 point scale). If score is missing, and patient died within 28 days after scheduled time for completion, the patient was considered deteriorated. In this case, time to deterioration is time to death.

Incidence and intensity of adverse events according to the United States National Cancer Institute (US NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 3.0

Clinically relevant changes in laboratory and ECG data

AUC (0-24); area under the concentration-time curve in plasma over the time interval from 0 to 24 hours for BI 6727 BS

AUC (0-24); area under the concentration-time curve in plasma over the time interval from 0 to 24 hours for CD 10899 BS (metabolite of Volasertib BI 6727)

AUC (0-inf); area under the concentration-time curve in plasma over the time interval from 0 extrapolated to infinity for BI 6727 BS

AUC (0-inf); area under the concentration-time curve in plasma over the time interval from 0 extrapolated to infinity for CD 10899 BS (metabolite of Volasertib BI 6727)

Cmax; maximum measured concentration of BI 6727 BS in plasma

Cmax; maximum measured concentration of CD 10899 BS (metabolite of Volasertib BI 6727) in plasma

tmax; time from dosing to maximum measured concentration of BI 6727 BS in plasma

tmax; time from dosing to maximum measured concentration of CD 10899 BS (metabolite of Volasertib BI 6727) in plasma

t1/2; Terminal half-life of BI 6727 BS in plasma

t1/2; Terminal half-life of CD 10899 BS in plasma

MRT; Mean residence time of BI 6727 BS in the body

CL; total clearance of BI 6727 BS in plasma after intravenous administration

Vss;apparent volume of distribution at steady state following intravenous administration for BI 6727 BS

This endpoint has not been statistically analysed in the study report

Volasertib (BI 6727 300 mg) was administered as intravenous infusion over 2 hours at Day 1 of each 21-day treatment course.

Treatment was to be administered until disease progression or occurrence of toxicity leading to treatment discontinuation. Patients withdrawn from volasertib treatment could receive a treatment according to investigator's choice. The patients were to be followed for survival status.

Volasertib (BI 6727)

Patients received a non-platinum cytotoxic single agent. The investigator chose the most appropriate drug according to patient status (previous chemotherapy effects, cumulative toxic effects, performance status, and nutritional status), the product Summary of Product Characteristics (SPC), and the local standard of care. The following non-platinum regimens were recommended because they are regarded efficacious and safe in patients with resistant ovarian cancer:

* Pegylated liposomal doxorubicin (PLD): 40 mg/m² at Day 1 (1 course = 28 days)
* Topotecan: 1.25 mg/m² from Days 1 to 5 (1 course = 21 days), or 4 mg/m² at Days 1, 8, and 15 (1 course = 28 days)
* Paclitaxel: 80 mg/m² at Days 1, 8, 15, and 21 (1 course = 28 days)
* Gemcitabine: 1000 mg/m² at Days 1 and 8 (1 course = 21 days)

Cytotoxic

Patients of the cytotoxic arm who switched to treatment with Volasertib (BI 6727).

Cytotoxic to Volasertib Switch

Total

Age, Continuous

Sex: Female, Male

Treated set (TS): The treated set consisted of all patients who received at least one administration of the trial drug.

Boehringer Ingelheim Call Center

Kaplan Meier estimates and confidence intervals (CI) were calculated using Greenwood's variance estimate within each treatment arm and the asymptotic CI for the difference in the rates found. The time was censored in those cases where there was no death or progression until the last trial visit

Disease Control Rate (DCR) at Week 24 According to Response Evaluation Criteria In Solid Tumours (RECIST) Version 1.1

Progression Free Survival (PFS)

Overall Survival (OS)

CR- Measurable disease

PR- Measurable disease

SD- Measurable disease

PD- Measurable disease

Missing- Measurable disease

CR- Non-measurable disease

Non-CR/Non-PD- Non-measurable disease

PD- Non-measurable disease

Missing- Non-measurable disease

Best Overall Response

Not evaluable

Missing

Biological Tumour Response Based on Serum Cancer Antigen 125 (CA-125) According to the Gynaecologic Cancer Intergroup (GCIG) Criteria

Biological Progression-free Survival Based on Serum Cancer Antigen 125 (CA-125) According to the Gynaecologic Cancer Intergroup (GCIG) Criteria

Time to Deterioration in Global Health Status/Quality of Life (QOL)

Time to Deterioration in Fatigue/Quality of Life (QOL)

Time to Deterioration in Pain/ Quality of Life (QOL)

Time to Deterioration in Abdominal Bloating/ Quality of Life (QOL)

Time to Deterioration in the Three Most Troublesome Disease Specific Symptoms/ Quality of Life (QOL)

Grade 1

Grade 2

Grade 3

Grade 4

Grade 5

Incidence and Intensity of Adverse Events According to the United States National Cancer Institute (US NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0

Blood alkaline phosphatase increased

Blood creatinine increased

Platelet count decreased

Alanine aminotransferase increased

Aspartate aminotransferase increased

Blood uric acid increased

Gamma-glutamyltransferase increased

Alanine aminotransferase abnormal

Electrocardiogram QT prolonged

Haemoglobin decreased

Neutrophil count decreased

Troponin I increased

Blood lactate dehydrogenase increased

Blood magnesium decreased

White blood cell count decreased

Blood urea increased

Alanine aminotransferase decreased

Blood bilirubin increased

Blood creatine phosphokinase decreased

Blood potassium decreased

Hepatic enzyme increased

Aspartate aminotransferase abnormal

Transaminases increased

Clinically Relevant Changes in Laboratory and ECG Data

Volasertib

All evaluable patients were to be included in the pharmacokinetic analysis. A patient was considered not evaluable if they had an important protocol violation relevant to the evaluation of pharmacokinetics or had insufficient data.

AUC (0-24); Area Under the Concentration-time Curve in Plasma Over the Time Interval From 0 to 24 Hours for BI 6727 BS

AUC (0-24); Area Under the Concentration-time Curve in Plasma Over the Time Interval From 0 to 24 Hours for CD 10899 BS

AUC (0-inf); Area Under the Concentration-time Curve in Plasma Over the Time Interval From 0 Extrapolated to Infinity for BI 6727 BS

AUC (0-inf); Area Under the Concentration-time Curve in Plasma Over the Time Interval From 0 Extrapolated to Infinity for CD 10899 BS

Cmax; Maximum Measured Concentration of BI 6727 BS in Plasma

Cmax; Maximum Measured Concentration of CD 10899 BS in Plasma

Tmax; Time From Dosing to Maximum Measured Concentration of BI 6727 BS in Plasma

Tmax; Time From Dosing to Maximum Measured Concentration of CD 10899 BS in Plasma

t1/2; Terminal Half-life of BI 6727 BS in Plasma

t1/2; Terminal Half-life of CD 10899 BS in Plasma

MRT; Mean Residence Time of BI 6727 BS in the Body

CL; Total Clearance of BI 6727 BS in Plasma After Intravenous Administration

Vss;Apparent Volume of Distribution at Steady State Following Intravenous Administration for BI 6727 BS

Biomarkers and Pharmacogenetics Analysis (Optional)

Overall Study

Infusion over 1 hour (1h) in course 1 and over 2 hours (2h) in course 2.

Infusion over 2 hours (2h) in course 1 and over 1 hours (1h) in course 2.

The primary objective of this trial is to identify the maximum tolerated dose (MTD) of BI 6727 therapy in terms of drug-related adverse events. Secondary objectives are the collection of overall safety and antitumour efficacy data and the determination of the pharmacokinetic profile of BI 6727.

BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours

An Open Phase I Single Dose Escalation Study of BI 6727 Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit

Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents, except for the following exclusions:

1. studies in products where Boehringer Ingelheim is not the license holder;
2. studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials;
3. studies conducted in a single center or targeting rare diseases (because of limitations with anonymization).

For more details refer to: https://www.mystudywindow.com/msw/datasharing

MTD is defined as: the dose of BI 6727 which is one dose tier below that dose at which two or more out of a maximum of six patients experienced dose-limiting toxicity (DLT). At the maximum tolerated dose, no more than one patient out of six patients may experience DLT, i.e. MTD is defined as the highest dose studied for which the incidence of dose-limiting toxicity is no more than 17% (i.e. 1/6 patients) during the first course.

DLT is defined as drug related common terminology criteria for adverse events (CTCAE) grade 3 or 4 non haematological toxicity (except emesis or diarrhoea responding to supportive treatment), or drug related CTCAE grade 4 neutropenia for seven or more days and / or complicated by infection, or CTCAE Grade 4 thrombocytopenia .

Number of participants with adverse events. The events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) v.3.0.

Grade refers to the severity of adverse event. Grade 1: Mild AE; Grade 2: Moderate AE; Grade 3: Severe AE; Grade 4: Life-threatening or disabling AE; Grade 5: Death related to AE.

Number of participants with clinically relevant abnormalities, occurring in \>5% of the total number of participants, is reported.

Clinically relevant post baseline values with Common Terminology Criteria for Adverse Events (CTCAE) grades:

* CTCAE grade ≥4 for White blood cell count (WBC) , Neutrophils (NEUT), NEUABS Lymphocytes (LMPH) if baseline CTCAE grade is not 4
* CTCAE grade ≥3 for Haemoglobin (HGB), Platelets count (PLTCT), Alkaline phosphatase (ALKP), serum glutamic-oxaloacetic-transaminase (SGOT), serum glutamic pyruvic transaminase (SGPT), total bilirubin (TBILI), if baseline CTCAE grade is ≥3 increases of one grade
* CTCAE grade ≥2 for other parameters, if baseline CTCAE grade is ≥2 increases of at least one grade

ECOG score: The scale of ECOG score is defined as a six point categorical scale as described ranging from 0 (asymptomatic) to 5 (death). ECOG score change from baseline to end of treatment is calculated, and defined as

= ECOG score at end of treatment - ECOG score at baseline.

Scale of ECOG score change:

The ECOG score changes from baseline score are categorized on a three point categorical scale: Improved, unchanged, and deteriorated. Improvement or deterioration of performance status required a decrease or an increase from baseline, respectively, of at least one point on the ECOG scale. The number of patients per category ("improved", "unchanged", "deteriorated" "unknown") is reported.

Electrocardiogram (ECG) - QTcF change from baseline. QTcF intervals form the ECGs were analysed for changes during and after intravenous infusion of BI 300 mg dose over 1 hours and over 2 hours. For baseline ECG, the combined baseline, defined as the mean of the 2 triplicates at the time-point closest to but prior to the start of the infusion of both treatment courses, i.e. a common baseline is used for both treatment courses, was used. Mean is adjusted mean.

Abbreviations:

QTcF: QT interval, corrected for heart rate according to Fridericia's formula (seconds) = measured QT / (cube root of preceding RR interval) QT: Interval from the beginning of the Q wave to the end of the T wave on an ECG (seconds).

CfB: Change from baseline.

Systolic blood pressure and diastolic blood pressure are reported.

For solid tumours, evaluation of tumour response was assessed according to the Response Evaluation Criteria in Solid Tumours (RECIST) definition. The overall response of target and non-target lesions together with or without the appearance of new lesions as reported by the investigator was assessed on a four point categorical scale as complete response (CR), partial response (PR), stable disease (SD), and progressive disease (PD) according to the RECIST criteria. In order to best handle measurements that were non-evaluable (NEV) a modified version of the RECIST criteria was used. If a RECIST overall response was deemed NEV, it could be further classified into non-evaluable clinically progressive disease (NEVCPD ) or non-evaluable clinically non-progressive disease (NEVCNPD), depending on the subjective assessment of the investigator.

Number of participants with progression of disease.

Progressive disease is defined according to the Response Evaluation Criteria in Solid Tumours (RECIST) as: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter.

Maximum concentration of BI 6727 in plasma (Cmax).

Different time frame for dose groups 300 mg BI 6727 1h2h and 300 mg BI 6727 2h1h:

For 300mg BI 6727 1h2h: At course 1: 0.083 hours before drug administration and at 1\*, 2, 4, 8, 24 hours after start of infusion (\*immediately prior to end of infusion of BI 6727).

For 300mg BI 6727 2h1h: At course 1: 0.083 hours before drug administration and at 1\*, 2, 3, 4 and 24 hours after start of infusion (\*immediately prior to end of infusion of BI 6727).

Time from dosing to maximum concentration (tmax).

Different time frame for dose groups 300 mg BI 6727 1h2h and 300 mg BI 6727 2h1h:

For 300mg BI 6727 1h2h: At course 1: 0.083 hours before drug administration and at 1\*, 2, 4, 8, 24 hours after start of infusion (\*immediately prior to end of infusion of BI 6727).

For 300mg BI 6727 2h1h: At course 1: 0.083 hours before drug administration and at 1\*, 2, 3, 4 and 24 hours after start of infusion (\*immediately prior to end of infusion of BI 6727).

Area under the concentration-time curve of BI 6727 in plasma over the time interval from 0 extrapolated to infinity (AUC0-inf).

Area under the concentration-time curve of BI 6727 in plasma over the time interval from 0 to the last quantifiable time point tz (AUC0-tz).

Different time frame for dose groups 300 mg BI 6727 1h2h and 300 mg BI 6727 2h1h:

For 300mg BI 6727 1h2h: At course 1: 0.083 hours before drug administration and at 1\*, 2, 4, 8, 24 hours after start of infusion (\*immediately prior to end of infusion of BI 6727).

For 300mg BI 6727 2h1h: At course 1: 0.083 hours before drug administration and at 1\*, 2, 3, 4 and 24 hours after start of infusion (\*immediately prior to end of infusion of BI 6727).

Terminal half-life of the analyte in plasma (t1/2).

Mean residence time of BI 6727 in the body after intravenous administration (MRT).

Total clearance of BI 6727 in the plasma after intravascular adminstration (CL).

Apparent volume of distribution at steady state following intravascular administration (Vss).

Apparent volume of distribution during the terminal phase λz following an intravascular dose (Vz).

Amount of BI 6727 that is eliminated in urine from the time point 0 to time point 24 hours (Ae0-24).

Amount of BI 6727 that is eliminated in urine from the time point 0 to time point 48 hours (Ae0-48).

Fraction of BI 6727 (percentage of dose) eliminated in urine from time point 0 to time point 24 hours (Fe0-24).

Fraction of BI 6727 (percentage of dose) eliminated in urine from time point 0 to time point 48 hours (Fe0-48).

Renal clearance of BI 6727 from the time point 0 to time point 24 hours (CLr,0-24).

Renal clearance of BI 6727 from the time point 0 to time point 48 hours (CLr,0-48).

Treated Set (TS): ALL patients who received at least one dose of BI 6727.

12 milligram (mg) solution for injection of BI 6727 was administered as intravenous infusion over 60 minutes once every 21 days (as long as there was clinical benefit for the patients).

12 mg BI 6727

24 mg solution for injection of BI 6727 was administered as intravenous infusion over 60 minutes once every 21 days (as long as there was clinical benefit for the patients).

24 mg BI 6727

48 mg solution for injection of BI 6727 was administered as intravenous infusion over 60 minutes once every 21 days (as long as there was clinical benefit for the patients).

48 mg BI 6727

75 mg solution for injection of BI 6727 was administered as intravenous infusion over 60 minutes once every 21 days (as long as there was clinical benefit for the patients).

75 mg BI 6727

125 mg solution for injection of BI 6727 was administered as intravenous infusion over 60 minutes once every 21 days (as long as there was clinical benefit for the patients).

125 mg BI 6727

200 mg solution for injection of BI 6727 was administered as intravenous infusion over 60 minutes once every 21 days (as long as there was clinical benefit for the patients).

200 mg BI 6727

300 mg solution for injection of BI 6727 was administered as intravenous infusion over 60 minutes once every 21 days (as long as there was clinical benefit for the patients).

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer	NCT01121406	Ovarian Neoplas...	Paclitaxel Gemcitabine Topotecan Pegylated lipos... BI 6727	18 Years -	Boehringer Ingelheim
BI 6727 Administered Intravenously Every 3 Weeks in Patients With Solid Tumours	NCT02273388	Neoplasms	BI 6727	18 Years -	Boehringer Ingelheim
Trial of BI 6727 (Volasertib) Monotherapy and BI 6727 in Combination With Pemetrexed Compared to Pemetrexed Monotherapy in Advanced NSCLC	NCT00824408	Carcinoma, Non-...	pemetrexed pemetrexed BI 6727	18 Years -	Boehringer Ingelheim
BI 6727 (Volasertib) Human ADME Trial in Various Solid Tumours	NCT01145885	Neoplasms	BI 6727	18 Years - 70 Years	Boehringer Ingelheim
BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour	NCT00969761	Neoplasms	BI-6727 BI 6727	18 Years -	Boehringer Ingelheim
BI 6727 (Volasertib) Randomised Trial in Ovarian Cancer	NCT01121406	Ovarian Neoplas...	Paclitaxel Gemcitabine Topotecan Pegylated lipos... BI 6727	18 Years -	Boehringer Ingelheim
Combination of BI6727 (Volasertib) and BIBF1120 in Solid Tumors	NCT01022853	Neoplasms	BI 6727 BIBF 1120	18 Years -	Boehringer Ingelheim
Dose Finding Study of BI 6727 (Volasertib) in Patients With Various Solid Cancers	NCT00969553	Neoplasms	BI 6727	18 Years -	Boehringer Ingelheim

Spots Global Cancer Trial Database for bi 6727

Every month we try and update this database with for bi 6727 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Spots Global Cancer Trial Database for bi 6727

Every month we try and update this database with for bi 6727 cancer trials from around the world to help patients and their families find trials that might be right for them. We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

Every month we try and update this database with for bi 6727 cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.